All In Biotech

Investigational drug · Phase 3

Quemliclustat

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Pancreatic Ductal Adenocarcinoma, Advanced Non-Small Cell Lung Cancer, Gastrointestinal Tract Malignancies.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

3

2 still active

All registered trials

14

Any phase or sponsor naming "Quemliclustat"

First trial start

2022

Jun 10, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Quemliclustat", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Advanced Non-Small Cell Lung Cancer
  • Gastrointestinal Tract Malignancies

Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Pancreatic cancer · Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "Quemliclustat" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 3 on PubMed

Also in development for Metastatic Pancreatic Ductal Adenocarcinoma

  • CadonilimabAK104Phase 331 trials

    Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

  • Telisotuzumab AdizutecanABBV-400Phase 316 trials

    AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer

  • ChiauranibCS2164Phase 33 trials

    Chipscreen Biosciences, Ltd. · Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Soft Tissue Sarcoma

  • TQB2868Phase 32 trials

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Pancreatic Neoplasms, Metastatic Pancreatic Ductal Adenocarcinoma

  • ponsegromabPhase 31 trial

    Pfizer · Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma

  • BotensilimabAGEN1181, 8541APhase 24 trials

    Agenus Inc. · Metastatic Colorectal Cancer, Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC), Untreated

  • JAB-23E73Phase 23 trials

    Jacobio Pharmaceuticals Co., Ltd. · Advanced Solid Tumor, Advanced Solid Tumors, Metastatic Pancreatic Ductal Adenocarcinoma

  • RMC-9805Phase 23 trials

    Revolution Medicines, Inc. · PDAC, Colorectal Cancer, CRC

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.